Experts explained the rise in prices for diabetes drugs

Medicines for the treatment of diabetes mellitus for 11 months of 2024 rose in price by 34.7% compared to the same period last year, the analytical company DSM Group calculated for Izvestia.

In addition, the cost of drugs for obstructive respiratory diseases increased - by 19.04%, as well as for hypolipidemic drugs - by 13.85%.

According to Nikolay Bespalov, Development Director of RNC Pharma, the reason for the increase in the price of diabetes drugs is that this group includes semaglutide drugs, which, although intended for the treatment of diabetes, are massively used not for the direct indication, but for the fight against excess weight.

Ozempic load: who makes money from the gray market of weight loss drugs

Illegal turnover of only one popular drug can reach 1.5 billion rubles a year

Bespalov attributed the increase in the average price of drugs for the treatment of obstructive respiratory diseases and hypolipidemic drugs to the growing demand for drugs from these groups.

Vadim Tkachenko, lawyer, founder and CEO of vvCube consulting group, is sure that the increase in the price of drugs from these groups is also due to the predominance of foreign-made drugs.

According to him, the cost is affected by the ruble exchange rate and increased logistics costs.

At the same time, retail consumption does not fall in packages, although the cost is growing, said Sergei Shulyak, General Director of DSM Group. The expert is confident that next year the level of consumption of drugs will remain the same, despite the rise in their cost.

Read more in the exclusive material "Izvestia":

Sugar fee: prices for diabetes drugs have risen by 35%